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ABSTRACT 
Objective: To synthesis a novel methodology of bioactive quinazoline derivatives under greener process to an excellent yields and increases their 
solubility via inclusion with β-cyclodextrin (CD).  
Methods: Derivatives of quinazoline compounds were prepared by the mixture of 3-amino-2-phenylquinazolin-4(3H)-one, derived from 2-phenyl-
4H-benzo[1,3]oxazin-4-one by refluxing with hydrazine, substituted aromatic aldehyde and alumina intimately in an agate mortar and pestle under 
solvent-free condition. Using various techniques for preparing inclusion complexes, kneaded method is the best method for encapsulation in host-
guest complex chemistry. All compounds including inclusion complexes were characterised by spectral methods.  
Results: Synthesized a series of novel quinazoline compounds under a very easier greener process with a commercially available reagent. However, 
their low bioavailability, due to low absorption and solubility, can limit their potential applications. CD was used to resolve this solubility problem. 
CD can easily accommodated the guest molecules to encapsulate inside its cavity due to interior the hydrophobic nature with a hydrophilic exterior 
part to form thermodynamically more stable molecular microcapsules, commonly name as host-guest complexes or inclusion complexes. In this 
sense, CD was utilized to enhance not only the solubility and bioavailability of these quinazoline compounds but also their antibacterial capacity. 
The formation of inclusion complex was thus confirmed by ultraviolet-visible spectroscopy (UV-VIS), Fourier Transform Infrared Spectrometry (FT-
IR), differential scanning calorimetry (DSC) and solubility study technique.  
Conclusion: Here we have successfully unfolded an eco-friendly methodology for the synthesis of derivatives of quinazoline and increased their 
solubility via host-guest inclusion technique. From the spectral analysis, it was concluded that the quinazoline compound is fully encapsulated 
inside the cavity of the CD.  
Keywords: 3-amino-2-phenylquinazolin-4(3H)-one, Substituted aldehyde, Inclusion complex, β-Cyclodextrin, Solubility study  




Quinazoline-4-(3H)-one moieties have gained wide-ranging research 
interest due to their broad spectrum range of biological activity. 
Quinazoline is an important studied moieties in medicinal field [1, 2]. 
At the beginning researches in the medicinal field started the 
febrifugine (3) discovery on the quinazoline scaffold which is a 
quinazolinone alkaloid, has immense anti-malarial activity from the 
plant aseru (dichroa febrifuge lour) [3, 4]. In addition, the anti-malarial 
activity [5], the derivatives of quinazoline demonstrate a broad range 
of biological activities including antibacterial [6, 7], anticancer [8, 9], 
antihypertensive [10], anti-inflammatory [11, 12], activities and so on 
(fig. 1). Even though their immense medicinal value to come out as 
successful drugs, water solubility, is one of the key factor [13]. 
  
 
Fig. 1: Representative some bioactive molecules containing quinazoline scaffold 
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In 2007, this work reported [14], from our laboratory under 
refluxing condition in ethanol solution to formation of a substituted-
3-(benzylideneamino)-2-phenylquinazolin-4(3H)-one and reported 
their anti-bacterial activity with quantitative structure-activity 
relationship (QSAR) studies. Now furthermore investigating a new 
methodology, we have synthesized this series of bioactive 
quinazoline moieties in a very easier greener technique under 
solvent-free protocol at 50 °C for 20 min using alumina as a catalyst 
that enhances the electrophilicity character of the carbonyl of 
respective aldehyde up to the product formation 90% (fig. 2). But 
one drawback of these series of compounds is fully water-insoluble, 
despite their immense medicinal property to come out as profitable 
drugs. Water solubility is part of the key factors to enhance the 
biological activity [15]. Here we tried to solve this problem through 
inclusion with β-cyclodextrin. Cyclodextrins (CDs) are homochiral, 
cyclic oligosaccharides belonging the family of 6, 7, or 8 member α-1, 
4-linkage D-glucopyranose units (namely α, β, and γ cyclodextrins), 
fully water-soluble and have cavity sizes ranging from 0.49 to 0.79 
nm [16, 19]. Most recently, this technique of complexion with 
cyclodextrins has been repeatedly applied in the preparation of oral 
bioavailability [20, 22]. In this technique, some drugs expand shelf 
life [23] to a certain extent, and furthermore, it contributes to 
control drug release rate, progressed organoleptic properties and 
maximized tolerance in gastrointestinal [24]. Thus, increased drugs 
solubility plays a very significant role in the absorption, which in due 
course affects its bioavailability [25]. Therefore it is very important 

























Fig. 2: Synthesis of substituted-3-(benzylideneamino)-2-phenylquinazolin-4(3H)-one using alumina as a catalyst 
 
MATERIALS AND METHODS 
The commercially available all reagents used here such as anthranilic 
acid, benzoyl chloride, pyridine, hydrazine, substituted aldehydes, 
cyclodextrin needed for molecules and ligand synthesis were used 
further without purification from the suppliers. Other reagents used 
throughout this work were purchased from the different companies 
sigma-aldrich, acros, thomas and baker, merck and were used as 
received except otherwise stated. Employed glassware was 
proceeding to reaction flame-dried or oven and cooled.  
Characterization of the compounds and inclusion complexes  
Nuclear magnetic resonance (NMR) spectroscopy  
1H-NMR (300 MHz) spectra and 13C-NMR (75 MHz) spectra were 
recorded on a Bruker Avance 300 spectrometer. Chemical shifts (δ) 
are given in parts per million (ppm) unit relative to reference as 
tetramethylsilane (TMS, δ 0.00 ppm). Coupling patterns are reflected 
in the following abbreviations: singlet (s), doublet (d), triplet (t), 
quartet (q), multiplet (m). Solvents are varied in each case.  
Ultraviolet-visible spectroscopy 
UV-VIS spectra were recorded on a JASCO V-530 Jasco, Tokyo, Japan 
spectrophotometer at room temperature in the wavelength range 
200–800 nm. The water solution of the complex was prepared with 
constant stirring and filtered the solution. UV spectra were recorded 
by using the filtered solution.  
Fourier transform infrared (FT-IR) spectroscopy 
Infrared (IR) spectra were recorded on a Schimadzu FTIR-8300 
spectrometer in the 4000–400 cm-1 region as in nujol. Only 
respective absorption bands are informed. Absorption is given in 
unit, wave numbers (cm−1); abbreviations: strong = s, medium = m, 
weak = w, broad = b.  
Differential scanning calorimetry (DSC)  
DSC studies were recorded in a Perkin Elmer Pyris 6. Temperature 
heating range and heating rate were done in the 30-250 °C and 5-10 
°C per min. 2-5 mg of sample was packed in aluminium pans.  
Mass spectroscopy  
The electron-spray mass spectra were taken on a MICROMASS 
QUATTRO II triple quadrupole mass spectrometer. FAB MS analyses 
were taken on a Jeol SX 102/Da-600 mass spectrometer. Data 
system using Argon/Xenon (6 kv, 10 mA) as the FAB gas. 10 kV was 
the accelerating voltage and spectra were made at room 
temperature.  
Thin-layer chromatography (TLC) 
TLC was performed for the compound, CD and inclusion compound 
using the eluent [ethyl acetate: butanol (5:4 v/v)] on TLC silica gel 
60 F254, Merck.  
Melting points (MP) 
MP was recorded in open glass capillaries using concentrated 
sulphuric acid bath and are uncorrected.  
General procedure for substituted-3-(benzylideneamino)-2-
phenylquinazolin-4(3H)-one using alumina as a catalyst 
Mixture of 3-amino-2-phenylquinazolin-4(3H)-one (1 mmol), 
substituted aromatic aldehyde (1 mmol) and alumina (4 equiv w. r. t. 
stating substance) were mixed intimately in an agate mortar and 
pestle for a period of 20-30 min under solvent-free condition. Then 
the mixture was heated in an oil bath at 50 °C. To this mixture, a few 
ml of water were added, filtered and dried the mass in an oven until 
to dryness. Then dried mass was dissolved in ethanol and collects 
the filtrate and evaporation of the solvent afforded the residue as a 
pure product. Purity of the product was checked by TLC on a TLC 
plate.  
3-{[(2-hydroxyphenyl) methylene] amino}-2-phenylquinazolin-
4(3H)-one[2a]: Yield 75%. m. p. 233 °C. IR ν (cm-1) (nujol): 3200-
3100, 1681, 1604, 1467. 1H NMR δ ppm CDCl3 (TMS): 6.69-8.36 (13H, 
m, Ar-H), 9.19 (1H, s, H-C=N), 9.99 (OH, H-bonded), 13C NMR δ ppm 
CDCl3 (TMS): 116.4, 117.5, 119.7, 121.5, 127.3, 127.4, 128.0, 128.9, 
130.3, 132.5, 133.3, 134.2, 134.8, 146.4, 153.6, 159.1, 159.7, 164.7. 
Anal. Calcd. for C21H15N3O2: C, 73.89; H, 4.45; N, 12.31; found: C, 
74.10; H, 4.45; N, 12.28. FAB MS (m/z): 342 (M+1).  
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3-{[(4-methoxyphenyl) methylene] amino}-2-phenylquinazolin-
4(3H)-one [2b]: Yield 80%. m. p. 210 °C. IR ν (cm-1) (nujol): 1679, 
1602, 1448, 1494, 1257, 1170. 1H NMR δ ppm CDCl3 (TMS): 3.84 
(3H, s,-OCH3), 7.37-8.36 (13H, m, Ar-H), 8.87 (1H, s, H-C=N-N); 13C 
NMR δ ppm CDCl3 (TMS): 55.4, 114.3, 121.5, 125.9, 126.9, 127.3, 
127.7, 127.9, 129.9, 129.9, 130.7, 134.4, 134.7, 146.5, 159.4, 163.0, 
164.0, 166.5. Anal. Calcd. for C22H17N3O2: C, 74.35, H, 4.82, N, 11.82; 
found: C, 74.40, H, 4.90, N, 11.78. FAB MS (m/z): 356 (M+1).  
3-{[(4-fluorophenyl) methylene] amino}-2-phenylquinazolin-
4(3H)-one [2c]: Yield 90%. m. p. ˃200 °C. IR ν (cm-1) (nujol): 1674, 
1614, 1593, 1554, 1537, 1469, 1373, 1184. 1H NMR δ ppm CDCl3 
(TMS): 7.10-8.70 (13H, m, Ar-H), 9.04 (1H, s, H-C=N); 13C NMR δ ppm 
CDCl3 (TMS): 166.3, 164.8, 153.9, 153.9, 146.6, 134.5, 134.1, 131.0, 
130.9, 130.5, 129.3, 128.9, 127.7, 127.2, 126.8, 121.5, 116.3. Anal. 
Calcd. for C21H14N3OF: C, 73.46, H, 4.11, N, 12.24; found: C, 73.50, H, 
4.10, N, 12.18. FAB MS (m/z): 344 (M+1).  
3-{[4-dimethylaminophenyl) methylene] amino}-2-phenyl-
quinazolin-4(3H)-one [2d]: Yield 75%. m. p. 240 °C. IR ν (cm-1) 
(nujol): 1681, 1589, 1556, 1508, 1456, 1375, 1328, 1313. 1H NMR δ 
ppm CDCl3 (TMS): 3.04 (-N-CH3), 6.68-8.70 (13H, m, Ar-H), 8.67 (1H, s, 
H-C=N); 13C NMR δ ppm CDCl3 (TMS): 187.6, 159.8, 154.0, 153.0, 146.7, 
134.8, 134.1, 130.7, 129.7, 129.3, 127.9, 127.7, 127.2, 126.8, 121.6, 
120.3, 111.5, 40.1. Anal. Calcd. for C23H20N4O: C, 74.98, H, 5.47, N, 15.2; 
found: C, 74.99, H, 5.50, N, 15.13. FAB MS (m/z): 344 (M+1). 
3-{[4-chloroyphenyl) methylene] amino}-2-phenylquinazolin-
4(3H)-one [2e]: Yield 85%. m. p. 196 °C. IR ν (cm-1) (nujol): 1679, 1591, 
1554, 1377. 1H NMR δ ppm CDCl3 (TMS): 7.37-8.36 (13H, m, Ar-H), 9.10 
(1H, s, H-C=N); 13C NMR δ ppm CDCl3 (TMS): 121.5, 127.1, 127.3, 127.9, 
127.9, 129.2, 129.8, 129.9, 130.0, 131.7, 134.4, 134.8, 138.5, 146.5, 154.0, 
159.2, 164.4. Anal. Calcd. for C21H14N3OCl: C, 70.10; H, 3.92; N, 11.68; 
found: C, 70.20; H, 4.10; N, 11.62. FAB MS (m/z): 360 (M+1). 
3-{[3-methoxyphenyl)methylene]amino}-2-phenylquinazolin-
4(3H)-one [2f]: Yield 82%. m. p. 234 °C. IR ν (cm-1) (nujol): 1679, 
1575, 1465, 1367, 1317, 1276. 1H NMR δ ppm CDCl3 (TMS): 3.74 
(3H, s,-OCH3), 7.30-8.37 (13H, m, Ar-H), 9.09 (1H, s, H-C=N-N); 13C 
NMR δ ppm CDCl3 (TMS): 111.7, 119.1, 121.7, 121.8, 122.3, 127.0, 
127.3, 127.9, 128.1, 128.2, 129.8, 134.2, 134.5, 134.9, 146.5, 154.1, 
159.3, 159.9, 165.5. Anal. Calcd. for C22H17N3O2: C, 74.35; H, 4.28; N, 
11.82; found: C, 74.45; H, 4.35; N, 11.78. FAB MS (m/z): 356 (M+1).  
3-{[(4-hydroxyphenyl)methylene]amino}-2-phenylquinazolin-
4(3H)-one [2g]: Yield 80%. m. p. 233 °C. IR ν (cm-1) (nujol): 3307, 
3213, 1668, 1645, 1604, 1554, 1375, 1338. 1H NMR δ ppm CDCl3 
(TMS): 5.03 (-OH), 7.42-8.29 (13H, m, Ar-H), 9.16 (1H, s, H-C=N-N); 
13C NMR δ ppm CDCl3 (TMS): 110.0, 120.1, 126.6, 127.0, 127.8, 128.2, 
129.2, 130.3, 133.9, 134.5, 134.5, 143.1, 149.0, 149.9, 155.0, 161.5. 
Anal. Calcd. for C21H15N3O2: C, 73.89; H, 4.43; N, 12.31; found: C, 
73.99; H, 4.49; N, 12.30. FAB MS (m/z): 342 (M+1).  
3-{[(4-hydroxy-3-methoxyphenyl)methylene]amino}-2-
phenylquinazolin-4(3H)-one [2h]: Yield 70%. m. p. ˃240 °C. IR ν 
(cm-1) (nujol): 3305, 3215, 1749, 1712, 1664, 1575, 1467, 1377. 1H 
NMR δ ppm CDCl3 (TMS): 3.81 (3H, s,-OCH3), 5.03 (-OH), 6.92-8.30 
(12H, m, Ar-H), 8.90 (1H, s, H-C=N-N); 13C NMR δ ppm CDCl3 (TMS): 
55.9, 108.7, 114.5, 125.4, 126.4, 126.6, 127.0, 127.3, 127.8, 128.2, 
129.3, 129.9, 130.3, 134.5, 143.2, 146.7, 147.3, 154.4, 159.8. Anal. 
Calcd. for C22H17N3O3: C, 71.15; H, 4.61; N, 11.31; found: C, 71.25; H, 
4.65; N, 11.26. FAB MS (m/z): 372 (M+1).  
3-{[(3-nitrophenyl)methylene]amino}-2-phenylquinazolin-
4(3H)-one [2i]: Yield 85%. m. p. 248 °C. IR ν (cm-1) (nujol): 1674, 
1641, 1500, 1456, 1344. 1H NMR δ ppm (CDCl3+DMSO-d6) (TMS): 
7.22-8.54 (12H, m, Ar-H), 9.58 (1H, s, Ar-H), 8.59 (1H, s, H-C=N); 13C 
NMR δ ppm (TMS) (CDCl3+DMSO-d6): 118.3, 120.6, 122.3, 122.3, 
126.9, 127.3, 127.9, 128.1, 128.9, 130.0, 131.5, 132.4, 133.5, 134.0, 
139.8, 161.6, 164.9, 165.5. Anal. Calcd. for C21H14N4O3: C, 68.10; H, 3.84; 
N, 15.15; found: C, 68.15; H, 3.81; N, 15.13. FAB MS (m/z): 371 (M+1).  
3-{[(pheny)lmethylene]amino}-2-phenylquinazolin-4(3H)-one 
[2j]: Yield 83%. m. p.196 °C. IR ν (cm-1) (nujol): 1662, 1647, 1645, 
1556, 1454. 1H NMR δ ppm (CDCl3+DMSO-d6) (TMS): 6.98-8.62 
(14H, m, Ar-H), 8.47 (1H, s, H-C=N); 13C NMR δ ppm (CDCl3+DMSO-
d6) (TMS): 119.8, 121.6, 122.8, 127.5, 127.7, 127.8, 128.7, 128.8, 
130.6, 132.1, 132.7, 133.6, 134.3, 139.8, 15.0, 165.8, 166.0. Anal. 
Calcd. for C21H15N3O: C, 77.52; H, 4.65; N, 12.91; found: C, 77.54; H, 
4.71; N, 12.85. FAB MS (m/z): 326 (M+1).  
Inclusion technique 
Formation of complexes 
In this portion, the complex is formed by the kneaded protocol and is 
characterized by UV, IR, DSC, and solubility study technique. It is 
examined that the effects of complex formation by β-CD showing 
improvement solubility of the compound in an aqueous medium. We 
developed different protocols for the complex formation and 
screened the most suitable protocol of its preparation. We worked 
only with compound 2a for complexation.  
 
 
Preparation of physical mixture (PM)  
The physical mixture of the compound 3-{[(2-hydroxyphenyl) 
methylene] amino}-2-phenylquinazolin-4(3H)-one and β-CD [1:1 
molar ratio] were prepared by mixing simultaneously in a mortar 
and pestle [26].  
Complex formation by kneading method (KN)  
To the best of our knowledge to design the most excellent formulation of 
inclusion complexes, a little volume of warm water was mixed with β-CD 
to make a slurry and then reserved at 50 °C for 12 h. The slurry was 
observed for 12 h with infrequent mauling. After 12 h, an equivalent 
amount of the 3-{[(2-hydroxyphenyl) methylene] amino}-2-phenyl-
quinazolin-4(3H)-one and the β-CD was mixed by triturating in a mortar 
and pestle with a small volume of water-ethanol mixture to form a 
slurry. The slurry was grinded for 45 min and dried at 50 °C. The dried 
mass was sieved through 100-micron mesh [27, 28]. 
Complex formation by co-evaporation method (COE)  
The aqueous solution of β-CD was mixed with an alcoholic solution 
of 3-{[(2-hydroxyphenyl) methylene] amino}-2-phenylquinazolin-
4(3H)-one. Then the mixture was stirred for 1 h and was evaporated 
to dryness at 45 °C. The dried mass was crushed and sieved through 
100 micron mesh [29].  
Complex formation by freeze-drying method (FD)  
The physical mixtures (PM) were taken in 500 ml double distilled 
water and stirred for 5 d. The resulting suspension was freeze-dried 
and freeze-dried complex. Thus formed was crushed and sieved 
through 100 micron mesh [30, 31]. 
Preparation of different water solution  
In distilled water (5 ml), β-CD (34 mg) solubilized to form clear 
solution, the physical mixture [3.34 mg said compound+17 mg β-CD 
(3 mmol: 3 mmol)] made a turbid suspension and the complex [3.34 
mg said compound+17 mg β-CD (3 mmol: 3 mmol)] was made to be 
faintly turbid as shown in fig. 6 (A, B, and C respectively).  
RESULTS AND DISCUSSION  
The initial reactant, 3-amino-2-phenylquinazolin-4(3H)-one (1) was 
synthesized in our laboratory following a method reported earlier. 
The reactants 3-amino-2-phenylquinazolin-4(3H)-one and 
substituted aldehyde were thoroughly mixed in an agate mortar and 
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pestle in presence of alumina at room temperature. Thereafter, the 
mixture was transferred to a round bottom flask and heated at 50 °C 
for 20-30 min. The corresponding product was isolated following by 
standard washing techniques [32]. 
All the compounds were characterized by NMR, FT-IR and Mass 
spectrometry. In the study of optimization, a model reaction was 
performed for the formation of 2j. The reaction was optimized with 
regards to the amounts of the lewis acid, temperature and the time 
for the reaction which has been summarized in table 1.  
To investigate the reaction optimization, initially, an equivalent 
mixture of the 3-amino-2-phenyl quinazolin-4(3H)-one and 
benzaldehyde at room temperature (RT) for 20 min but TLC plate 
did not exhibit any new spot. Thereafter, the temperature was 
increased to 50 °C, wherein 30% conversion was obtained. (table 1, 
entry 2). For further rationalization we used alumina (2 equiv w. r. t 
substrates) as a catalyst at the same temperature condition, 
wherein, the conversion is about 60% (table 1, entry 3). Gradual 
increase in concentration of alumina up to 4 equivalents of alumina 
w. r. t substrates, keeping other experimental conditions identical, 
resulted in corresponding increase in product, i.e., 83%. Thereafter, 
the further increase in alumina did not respond with hike in product 
yield. Therefore, the reaction was optimized with 4 equivalents of 
alumina w. r. t substrates at 50 °C for 20 min (table 1, entry 5). 
  
Table 1: Optimized table for formation of 3-(benzylideneamino)-2-phenylquinazolin-4(3H)-one using alumina as a catalyst 
Entry Alumina (equiv) Time (min) Temp ( °C) Yield (%) 
1 __ 20 RT no reaction 
2 __ 20 50 30 
3 2 20 50 60 
4 3 20 50 77 
5 4 20 50 83 


























































30 min, 75% 25 min, 80% 20 min, 90%
30 min, 75% 20 min, 85% 25 min, 82%
30 min, 80% 30 min, 70% 20 min, 85%
20 min, 83%
 
Fig. 3: Substrate scope of alumina catalyst substituted-3-(benzylideneamino)-2-phenylquinazolin-4(3H)-one 
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For more insight on the diversity of the catalyst, the reaction was 
studied with different substrates varying in the nature of the 
substituent, i.e., electron withdrawing and electron donating (fig. 3) at 
optimised condition [33]. Both types of the substituent responded 
appreciably in this reaction condition. In the case of electron 
withdrawing substituent such as-F,-Cl,-NO2 etc., the conversion of the 
reaction is high. This is largely due to the increasing electrophilicity of 
the carbonyl carbon of the corresponding aldehyde. When 4-
fluorobenzaldehyde reacts with 3-amino-2-phenylquinazolin-4(3H)-
one (1:1), conversion occurs up to 90% (fig. 3, entry 2c) due to the 
very high electronegativity of fluorine atom which withdraws electron 
through inductive effect directly, thereby increaseing the 
electrophilicity at the carbonyl carbon leading to the improved 
reaction yield. In case of-Cl (85%, fig. 3, entry 2e) and-NO2 (85%, fig. 3, 
entry 2i), yields are slightly lower as compared to-F because-Cl 
showed the low inductive effect while the nitro group present in meta 
position do not participate in resonance effect. For similar reasons, in 
the case of the electron donating substituent such as-OCH3,-NMe2,-OH, 
product conversion is slightly reduced due to increase in the electron 
availability in the carbonyl carbon of aldehyde group. When these 
groups are directly connected in the ortho or para position w. r. t 
aldehyde group, conversion of the desired products yields excellent to 
moderate. When in the meta position, product conversion is enhanced 
up to 82% (fig. 3, entry 2f). Very interestingly, when the reaction takes 
place only with benzaldehyde that is no substituent are incorporated 
in the aryl ring still product conversion 83% (fig. 3, entry 2j) since aryl 
ring shows both inductive as well as resonance effect. For this 
behaviour, it converted the reaction yield up to 83% in between 
donating and withdrawing substituent.  
Mechanism 
Using alumina as a catalyst not only enhances the carbonyl character 
through electrophilicity but also acts as a powerful desiccant that 
improved the reaction towards the forward direction by forcing 
dehydration to produce the desired product (fig. 4). Alumina bind 
with carbonyl to activate the central facilitate the nucleophilic attack 
of the formation of intermediate (3). Finally a molecule of water 
























Fig. 4: Plausible mechanisms for solvent-free synthesis of substituted-3-(benzylideneamino)-2-phenylquinazolin-4(3H)-one using alumina 
 
UV-VIS spectroscopic study  
From the absorption spectra, the corresponding absorbance of the 
compound was varied due to the formation of the complex as 
showed in fig. 5. In the complex formed through physical mixtures 
without the addition of water are very slow as compared to the 
complex formed from the kneading method which contained water 
during crushing. The study demonstrates that the dissolution rate of 
3-{[(2-hydroxyphenyl)methylene]amino}-2-phenylquinazolin-
4(3H)-one was increased to such an extent by using kneading 
method for complex formation as compared to other methods.  
 
 
Fig. 5: Efficiency of diverse methods for the complex formation 
 
Thereafter, the crushing time for the complex preparation was 
varied as: 0 min, 20 min, 30 min, 40 min, 60 min. The mixture of β-
CD and compounds (1:1) was added in each preparation. It may be 
emphasized that crushing time has an important role in the complex 
formation. With increasing crushing time there is a pronounced 
increase in absorbance of the reaction mixture. Beyond 40 min of 
crushing, an absorbance of the drug with β-CD showed a plateau 
which indicated that the optimum condition (fig. 6). Therefore, the 
optimized kneading time was found to be 40 min. No such high 
absorption was observed for the quinazolone and CD in the range 
270-300 nm, while a high absorption was found for the inclusion 
complex in 270-300 nm region. Moreover, from this UV spectrum, it 
can be concluded that there must be an inclusion complex [34, 35].  
 
 
Fig. 6: UV spectrum of complex formation in various crushing time 
 
Infrared studies 
The IR spectrum of β-CD, 3-{[(2-hydroxyphenyl) methylene] amino}-
2-phenylquinazolin-4(3H)-one (2a), physical mixture (1:1 molar 
ratios) as well as the complex formation under kneaded method are 
shown in below (fig. 7). In the drug-loaded compound, the essential 
bands are carbonyl (-C=O), imine (-C=N), amine (-C-N), aromatic-C-H 
(stretching and out of a plane, bent), alcoholic-OH (H-bonding) and 
aromatic-C=C group. Analysis of the IR spectrum of both a physical 
mixture and inclusion complexes are observed in a changing 
frequency or hidden or lower the intensity of the spectrum band.  
The spectrum of 2a showed a separate peak in the ~1651 cm-1, 
indicating the presence of carbonyl group which ranges at 1700-1650 
cm-1. The band in ~1604 cm-1regions was assigned to imine (-C=N), the 
band in ~1280 cm-1was represented to amine vibration band (-C-N), 
aromatic-C=C skeleton vibrations band was observed in ~1530 cm-1, 
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the bands at ~758 and ~702 cm-1 were corresponded to the out of 
plane and bending vibration of aromatic-C-H. Moreover, the aromatic-
CH stretching band region which appear at 3064 cm-1 are shifted 
towards shorter wave number. The band was also observed in ~3216 
cm-1 to the represent-OH group which showed some disappearance 
(due to H-bonding, the normally-OH band appears at 3400-3600 cm-1 
regions). In the case of β-CD, a broadband was appeared at ~3300 
cm−1 could be alloted to the numerous hydrogen bonds (fig. 7). 
The spectrum of PM was the simple mixture of 2a and β-CD, several 
characteristic bands of 2a and the typical broadband of β-CD at 
~3300 cm−1 were straightforwardly found, indicating that 2a and β-
CD were independently belonged to each other without any 
interaction. But for the inclusion complex, the characteristic bands of 
2a were completely disappeared. The shape, intensity, shift or 
disappearance of these bands varied dramatically for the complex as 
compared to those for pure drug and physical mixture. These 
pointed out that the bending and vibrating of the guest molecule, [3-
{[(2-hydroxyphenyl)methylene]amino}-2-phenylquinazolin-4(3H)-
one], 2a, was restricted owing to the formation of a complex, 
suggesting a new structure was fig. out and the guest molecule was 
entirely inserted into the internal hole of β-CD [36, 37]. 
  
 
Fig. 7: IR spectrum of A) drug (2a) and B) drug (2a), cyclodextrin (CD), physical mixtiure (PM) and complex (KN), [blue line= drug; red 
line= complex; black line= CD; green line= PM] 
 
Differential scanning calorimetry studies 
DSC is a very helpful technique to find inclusion complexes. When 
guest molecules were entirely or partly inserted into the cavity 
portion of CD, their sublimation, boiling and melting points would all 
shift to a lower temperature or intencity towards lower or even 
vanished [38, 39]. The DSC thermograms of drug (2a), CD, physical 
mixtures (1:1) and complex (1:1) are shown in fig 8. Drug was 
characterized by a single, sharp melting endotherm at 234.6 °C (∆H= 
88.71 J/g) in the time of DSC analysis and a broad endothermic 
thermogram of CD are observed at a maximum around 97 °C 
respectively, mainly due to release of a molecule of water, 
encapsulated into β-CD cavity during heating. In the case of complex, 
the drug endotherm almost disappeared along with a shift to 231.6 °C 
and the peak which arises from CD are shifted to 104 °C 
approximately, which was indicated to be caused by inclusion complex 
of the drug molecules in the cavity inside of CD to substitute a fraction 
of molecules of water [40]. Peak intencity was reduced but not as that 
of complex and temperature shifted to lower in case of a physical 
mixture. On the basis of above outcomes, it was indicated that 2a-β-CD 
was successfully made with the hydrophobic parts of the drug 
molecule being incorporated inside the cavity of β-CD to form the 
inclusion complex, commonly called ‘host-guest’ complex [41].  
 
 
Fig. 8: DSC thermograms of drug (2a), cyclodextrin (CD), 
physical mixture (PM) and complex (KN). [mentioned with 
respective colour] 
Solubility studies 
Inclusion complexes made by different protocols were primarily 
illustrated by the degree of transparency of the drug of the solution 
prepared in water. In fig. 9. it may be seen that solubility of the 
complex was increased as compared to the physical mixture [42]. 
This transparency indicated that there exists interaction between 
host and guest molecule. A comparative study was done on silica-gel 
plates (TLC) using the eluent [ethyl acetate: butanol (5:4 v/v) ]. 
Spots of β-CD and the compound were observable with slight trailing 
off spot of the compound for the physical mixture (PM) while in the 
complex a concentrated bulk trailing was examined with faint spot 
compared of the free compound. The appearance of the faint trailing 
spot indicated that of the slow diffusion of the compound in the TLC 
study in the used eluent. This further corroborates the reported 
study that the molecule, 2a, must be encapsulated inside the cavity 
of β-CD through ‘host-guest’ complexation.  
 
 




In summary, we have developed a new synthetic route for the 
synthesis of substituted-3-(benzylideneamino)-2-phenylquinazolin-
4(3H)-one using a greener reagent in a very short span under 
solvent-free condition with excellent yield. In the reported back all 
these compounds are biologically active but low solubility in the 
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water medium. Herein we have tried to develop the solubility in an 
aqueous medium of this synthesized molecule. Finally, we have 
unfolded the solubility problem through inclusion with β-
cyclodextrin. For preparing a complex with β-cyclodextrin to 
increase solubility, the kneaded method is the best method among 
the all other mentioned method. The bioavailability of the drug 
molecule has been found to be high which promises potential 
pharmaceutical application. 
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